Our findings, using an established missense variant in GIPR to proxy impaired GIPR signaling, suggest potential adverse effects of downregulated GIPR signaling on breast cancer risk and, thus, possible protective effects of pharmacological GIPR agonism. Here, GIPR is linked to breast carcinoma.